# US 2024/0189440 A1 · Tlr7 and tlr8 agonists for the treatment of cancer and/or infectious diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189440 A1
- Document ID: US20240189440A1
- Status: Published application
- Kind: A1
- Application number: 18/547,594
- Filed: 2022-03-01
- Published: 2024-06-13
- Earliest claimed: 2021-03-02
- Assignees: The Research Foundation for The State University of New York
- Applicants: The Research Foundation for the State University of New York
- Inventors: Lawrence Nathan TUMEY; Emmanuel OLAWODE
- Web page: https://patentgrep.com/patent/US20240189440A1

## CPC

- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are compounds of the Formula (I) or (II) or (III): Also disclosed are methods for stimulating an immune response, inducing an anti-tumor immune response, and treating an infectious disease in a subject by administering a therapeutically effective amount of a compound disclosed herein. Also disclosed are methods of treating a tumor or abnormal cell proliferation by administering a therapeutically effective amount of a compound disclosed herein under conditions effective to treat a tumor or abnormal cell proliferation.

## Claims

### Claim 1

A compound of the Formula (I) or (II)
wherein:
R1 is selected from C1-C10 alkyl, C1-C10 oxaalkyl, and C1-C10 azaalkyl;
R2 and R3 are each independently selected from hydrogen, C1-C5 alkyl, and C1-C5 alkoxy;
n is 1 or 2
Y is independently selected from optionally substituted aryl and optionally substituted heteroaryl;
Z1 is selected from —NRZ—, —O—, —NRZC(O)—, —NRZC(O)—O—, and —NRZSO2—;
Z2 is absent, or is selected from (C1-C8)hydrocarbon-NH— and a 5- to 8-membered nitrogen-containing heterocycle, wherein a nitrogen of the heterocycle is attached to X2;
Z is independently selected from —NRZ—, —NRZC(O)—, and —O—;
RZ is independently selected in each instance from hydrogen, C1-C8 hydrocarbon, C1-C8 oxaalkyl, C1-C8 azaalkyl, heteroaryl, and a 5- to 8-membered heterocyclic ring;
X1 is independently selected from RZ, —C(O)—RZ, —C(O)—O—RZ, —C(O)—N—(RZ)2, —(CH2)kNRZC(O)—(C1-C6)alkyl, —(CH2)kNRZC(O)—O—(C1-C4)alkyl, and —SO2—RZ;
k is an integer from 1 to 8;
X2 comprises cleavable or noncleavable linker; and
Ab comprises an antibody or an antibody fragment.

### Claim 2 (depends on 1)

The compound according to claim 1, of the Formula (I) or (II)
wherein:
R1 is selected from C1-C10 alkyl, C1-C10 oxaalkyl, and C1-C10 azaalkyl;
R2 and R3 are each independently selected from hydrogen, C1-C5 alkyl, and C1-C5 alkoxy;
n is 1 or 2
Y is independently selected from optionally substituted aryl and optionally substituted heteroaryl;
Z1 is selected from —NRZ—, —O—, —NRZC(O)—, —NRZC(O)—O—, and —NRZSO2—;
Z2 is absent, or is selected from (C1-C8)hydrocarbon-NH— and a 5- to 8-membered nitrogen-containing heterocycle, wherein a nitrogen of the heterocycle is attached to X2;
Z is selected from —NRZ— and —O—;
RZ is independently selected in each instance from hydrogen, C1-C8 hydrocarbon, C1-C8 oxaalkyl, C1-C8 azaalkyl, heteroaryl, and a 5- to 8-membered heterocyclic ring;
X1 is independently selected from RZ, —C(O)—RZ, —C(O)—O—RZ, —C(O)—N—(RZ)2, and —SO2—RZ;
X2 comprises cleavable or noncleavable linker; and
Ab comprises an antibody or an antibody fragment.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

A compound according to claim 1, wherein:
X2 is L1-L2-(L3)p-(L4)q-(L5)r;
L1 is a conjugation moiety;
L2 is a spacer unit selected from branched or unbranched C1-C12 alkyl, a PEG selected from PEG1 to PEG12,
L3 is a peptide of 1 to 6 amino acids;
L4 is a self-immolative spacer;
L5 is carbonyl; and
p, q, and r are each independently selected from 0 and 1, wherein when p and q are each 0, r must be 0.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein said compound is of Formula (I), and:
R1 is selected from n-butyl, —CH2OH, and —CH2OCH2CH3;
R2 and R3 are each hydrogen;
n is 1;
Y is phenyl or pyridyl, each of which is unsubstituted or substituted with one or more of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
X1 is hydrogen; and
Z1 is —N(RZ)— or —O—.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein said compound is of Formula (II), and:
R1 is selected from n-butyl, —CH2OH, and —CH2OCH2CH3;
R2 and R3 are each hydrogen;
n is 1;
Y is phenyl or pyridyl, each of which is unsubstituted or substituted with one or more of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
X1 is hydrogen; and
Z is —N(RZ)— or —O—.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is the compound of formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih):
wherein represents a point of attachment to X2.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound of Formula (II) is the compound of formulae (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (IIh):
wherein represents a point of attachment to X2.

### Claim 10 (depends on 4)

The compound of claim 4, wherein:
L1 is selected from:
L2 is selected from
L3 is
wherein R is an amino acid side chain;
L4 is selected from:
L5 is
and
p, q, and r are each independently 0 or 1, wherein when p and q are each 0, r must be 0.

### Claim 11 (depends on 10)

The compound of claim 10, wherein L3 is selected from ValCit, GlyValCit, ValArg, PheLys, AlaAla, GlyGlyPheGly, AlaAlaAla, AlaAsn, AsnAsn, AsnAla, ValCitGlyPro, AsnGlyPro, AsnAsnGlyPro, Asn, GlyAsn, AsnAla, ProCitAla, ProAsnLeu, ProAsnAla, ProPheAla, ProPheGly, ProCitLeu, ProAsnPro, ProAsnSer, and ProAsnGly.

### Claim 12 (depends on 10)

The compound of claim 10, wherein:
L1 is selected from:
L2 is
L3 is ValCit, GlyValCit, AsnAsn, Asn or AlaAla;
L4 is selected from:
L5 is
and
p, q, and r are each 0 or p, q, and r are each 1.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein X2 is attached to Ab through a cysteine residue of Ab, a lysine residue of Ab, or a glutamine residue of Ab; or wherein Ab is a tumor targeting antibody, an antibody fragment, a bispecific antibody or antibody fragment, a monoclonal antibody, a chimeric antibody, or a humanized antibody.

### Claim at position 14

14-15. (canceled)

### Claim 16

A compound of the Formula (III)
wherein:
R1 is selected from C1-C10 alkyl, C1-C10 oxaalkyl, and C1-C10 azaalkyl;
R2 and R3 are each independently selected from hydrogen, C1-C5 alkyl, and C1-C5 alkoxy;
n is 1 or 2;
Y is selected from optionally substituted aryl and optionally substituted heteroaryl;
ZA is selected from —NRZ—, —NRZC(O)—, —NRZC(O)—O—, —NRZC(O)—(CH2)k—NH—, —NRZC(O)—(CH2)k—O—, —C(O)—O—(CH2)k—O—, —NRZC(O)—(CH2)k—N(CH3)—, —NRZC(O)—O—(CH2)k—NH—, —NRZC(O)—(CH2)k—NH—C(O)—O—, and —NRZSO2—;
k is an integer from 1 to 8;
RZ is selected from hydrogen, C1-C8 hydrocarbon, C1-C8 oxaalkyl, C1-C8 azaalkyl, heteroaryl, and a 5- to 8-membered heterocyclic ring; and
XA is selected from hydrogen, C1-C10 alkyl, and —C(O)CH3,
wherein the following compound is excluded:

### Claim 17 (depends on 16)

The compound of claim 16, wherein:
R1 is selected from n-butyl, —CH2OH, and —CH2OCH2CH3;
R2 and R3 are each hydrogen;
n is 1;
Y is phenyl or pyridyl, each of which is unsubstituted or substituted with one or more of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy; and
RZ, when present, is hydrogen.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R1 is n-butyl and Y is unsubstituted phenyl; and/or wherein ZA is selected from —NRZ—, —NRZC(O)—, —NRC(O)—O—, —NRZC(O)—(CH2)k—NH—, —N C(O)—O—(CH2)k—NH—, —N C(O)—(CH2)k—NH—C(O)—O—, and —NRZSO2—.

### Claim 19

(canceled)

### Claim 20 (depends on 19)

The compound of claim 19, wherein ZA—XA is selected from —NHC(O)O(C1-C4)alkyl, —NH2, —NHC(O)(CH2)kNH2, —NHC(O)(CH2)kNH—C(O)O(C1-C4)alkyl, and —NHC(O)(C1-C4)alkyl.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the compound of any claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method for stimulating an immune response in a subject, the method comprising administering a therapeutically effective amount of the compound of claim 1 under conditions effective to stimulate an immune response.

### Claim at position 23

24-25. (canceled)

### Claim 26 (depends on 1)

A method for inducing an anti-tumor immune response in a subject, the method comprising administering to a therapeutically effective amount of the compound of claim 1 under conditions effective to induce an anti-tumor immune response.

### Claim at position 25

27-28. (canceled)

### Claim 29 (depends on 1)

A method for treating a tumor or abnormal cell proliferation, said method comprising administering a therapeutically effective amount of the compound of claim 1, under conditions effective to treat a tumor or abnormal cell proliferation.

### Claim at position 27

30-31. (canceled)

### Claim 32 (depends on 1)

A method for treating an infectious disease, said method comprising: administering a therapeutically effective amount of the compound of claim 1, under conditions effective to treat an infectious disease.

### Claim at position 29

33-36. (canceled)
